MEDIUM confidence: 100% data completeness, but the composite (52) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Avg target $123 (last qtr, 7 analysts) → $125 (last mo, 5) (+2.1%).
Buy-rated share 75% → 74% over ~3 months (-1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $1.28 | $1.31 | +2.3% |
| Apr 2026 | $1.14 | $1.15 | +0.9% |
| Jan 2026 | $1.50 | $1.50 | +0.0% |
| Oct 2025 | $1.30 | $1.30 | +0.0% |
| Jul 2025 | $1.26 | $1.26 | +0.0% |
| Apr 2025 | $1.07 | $1.09 | +1.9% |
| Jan 2025 | $1.34 | $1.34 | +0.0% |
| Oct 2024 | $1.20 | $1.21 | +0.8% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $43.1B— | $43.7B+1.3% | $40.1B-8.1% | $42.0B+4.6% | $44.3B+5.7% |
| EPS (dil.) | $3.94— | $3.91-0.8% | $3.27-16.4% | $7.64+133.6% | $3.72-51.3% |
| Free Cash Flow | $8.6B— | $7.8B-9.8% | $5.1B-35.2% | $6.4B+25.5% | $7.4B+16.4% |
| Gross Margin | 53.9% | 51.1%-2.8pp | 50.0%-1.2pp | 50.8%+0.9pp | 55.5%+4.7pp |
| Operating Margin | 21.4% | 19.2%-2.2pp | 16.0%-3.1pp | 16.3%+0.2pp | 18.2%+1.9pp |
| Net Margin | 16.4% | 15.9%-0.5pp | 14.3%-1.6pp | 31.9%+17.7pp | 14.7%-17.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider $816K over 180 days (3 open-market buys, 6 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 7.5%/yr (revenue basis).
Base free cash flow $6.3B (avg FY2023–FY2025; latest year $7.4B) · equity value $191.9B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 52 for Abbott Laboratories indicates a neutral outlook, with the stock's long-term and short-term scores relatively aligned. The stock scores high on profitability, with a robust gross margin of 56.8%, and exhibits low risk, with a beta of 0.6. However, it trades at a premium, with a P/E of 35.7, and exhibits weak growth, driven by a decline in EPS growth of 51.2%. Momentum is mixed, with a strong 3-month return of 31.5% but a negative 12-month return of 15.6%.